COVID-19 Information Hub

Made for the world

We are committed to changing the course of the pandemic with a vaccine made for the world. No one is safe until all of us are safe.

For more information, please visit our newly launched website.

Our response to COVID-19

The COVID-19 pandemic is a challenge to humanity that demands a global, united response, not just from the scientific community but also from industry, organisations, governments and every single person around the globe.

Since early 2020 when the true scale of the crisis became clear, AstraZeneca has committed to help defeat COVID-19 by harnessing and sharing our scientific knowledge and expertise to advance and accelerate the development of potential medicines to prevent or treat the virus.

We have donated nine million face masks to support healthcare workers in 49 countries, bolstered national COVID-19 testing effort and initiated clinical trials to investigate our new and existing medicines to see how they could treat the infection.

Recognising the urgent need for a vaccine to defeat the virus, we joined forces with the University of Oxford, bringing together its world-class expertise in vaccinology with our global development and manufacturing capabilities. We have accelerated clinical development and rapidly mobilised partnerships and a global supply chain that will support a broad, timely and equitable supply of a safe and effective vaccine around the world, if approved, and at no profit during the pandemic.

Complementing our vaccines approach, we also quickly mobilised research efforts to advance the development of a novel coronavirus-neutralising long-acting antibody combination (LAAB) for the potential prevention and treatment of COVID-19.

With the COVID-19 pandemic continuing to claim thousands of lives every day, we are moving quickly with our clinical trials while following strict regulatory standards, and good clinical practice and guided by robust independent data safety and monitoring boards. Given the unprecedented global impact of COVID-19 and the need for public information, we are committed to being transparent about this process.

Bolstered by our resiliency, our employees have maintained momentum, drawing motivation from our values to follow the science, do the right thing and put patients first.

Our priorities remain to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities.

Latest news

AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial

11 October 2021

Corporate Press Release

AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US

5 October 2021

Corporate Press Release

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

29 September 2021

AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases

27 September 2021

Corporate Press Release

AstraZeneca and European Commission reach settlement agreement over vaccine supply, ending litigation

3 September 2021

Corporate Press Release

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19

20 August 2021

Corporate Press Release

Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people

28 July 2021

Corporate Press Release

Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose

28 July 2021

Corporate Press Release

Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern

23 July 2021

Corporate Press Release

Vaxzevria induced immunity for at least 1 year following a single dose and strong immune responses following either a late second dose or a third dose

28 June 2021

Corporate Press Release

First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated

27 June 2021

Corporate Press Release

AstraZeneca welcomes Court ruling on supply of its COVID-19 vaccine to Europe

18 June 2021

Corporate Press Release

COVID-19 Vaccine AstraZeneca effective against Delta (‘Indian’) variant

15 June 2021

Corporate Press Release

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

15 June 2021

Corporate Press Release

AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan

21 May 2021

Corporate Press Release

The European Medicines Agency reaffirms that the overall benefits of AstraZeneca’s COVID-19 vaccine continues to outweigh risks

27 April 2021

Update on the DARE-19 Phase III trial for Farxiga in COVID-19

12 April 2021

Corporate Press Release

Significant milestone reached as 100 countries receive vaccine through COVAX

8 April 2021

Update following MHRA and EMA decisions on AstraZeneca’s COVID-19 vaccine

7 April 2021

AZD1222 US Phase III primary analysis confirms safety and efficacy

25 March 2021

Corporate Press Release

Statement on COVID-19 vaccine supply at Anagni plant in Italy

24 March 2021

Corporate Press Release

Update following statement by NIAID on AZD1222 US Phase III trial data

23 March 2021

Corporate Press Release

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

22 March 2021

Corporate Press Release

UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective

18 March 2021

Corporate Press Release

AstraZeneca to supply the US with up to half a million additional doses of the potential COVID-19 antibody treatment AZD7442

16 March 2021

Corporate Press Release

Update on the safety of COVID-19 Vaccine AstraZeneca

14 March 2021

Corporate Press Release

AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX

2 March 2021

Corporate Press Release

First real-world study of COVID-19 Vaccine AstraZeneca demonstrates 94% reduction in hospitalisations

23 February 2021

COVID-19 Vaccine AstraZeneca receives provisional approval for use in Australia

16 February 2021

AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization

15 February 2021

Corporate Press Release

COVID-19 Vaccine AstraZeneca receives interim recommendations for use by World Health Organization experts

10 February 2021

AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

10 February 2021

Corporate Press Release

COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials

3 February 2021

Corporate Press Release

COVID-19 Vaccine AstraZeneca authorised for use in the EU

29 January 2021

Corporate Press Release

COVID-19 Vaccine AstraZeneca recommended for use in the EU

29 January 2021

Corporate Press Release

AstraZeneca’s COVID-19 vaccine: European Union supply commitment

27 January 2021

Serum Institute of India obtains emergency use authorisation in India for AstraZeneca’s COVID-19 vaccine

6 January 2021

Corporate Press Release

AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK

30 December 2020

Corporate Press Release

Update on application for conditional marketing authorisation for the AstraZeneca COVID-19 vaccine to the European Medicines Agency

30 December 2020

AZD1222 Oxford Phase III trials interim analysis results published in The Lancet

8 December 2020

Corporate Press Release

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

23 November 2020

Corporate Press Release

FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trial

23 October 2020

Corporate Press Release

COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials

9 October 2020

Corporate Press Release

COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India

2 October 2020

Corporate Press Release

COVID-19 vaccine AZD1222 clinical trials resumed in the UK

12 September 2020

Corporate Press Release

Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause

9 September 2020

Corporate Press Release

Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups

31 August 2020

Corporate Press Release

AstraZeneca’s scientific and social commitment for COVID-19 vaccine

31 August 2020

Corporate Press Release

Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19

25 August 2020

Corporate Press Release

AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine

14 August 2020

Corporate Press Release

COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial

20 July 2020

Corporate Press Release

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

13 June 2020

Corporate Press Release

Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients

5 June 2020

Corporate Press Release

AstraZeneca takes next steps towards broad and equitable access to Oxford University’s COVID-19 vaccine

4 June 2020

Corporate Press Release

AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford’s potential new vaccine

21 May 2020

Corporate Press Release

AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine

30 April 2020

Corporate Press Release

AstraZeneca joins UK Government’s ACCORD trial platform

28 April 2020

AZ and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients

23 April 2020

Corporate Press Release

AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19

14 April 2020

Corporate Press Release

AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19

24 March 2020

Corporate Press Release

Latest articles

Bridging the vaccine gap threatening Africa

11 August 2021

Pascal Soriot calls for global cooperation in the fight against COVID-19 and climate change

2 August 2021

AstraZeneca’s COVID-19 vaccine shows effectiveness against Indian variants of SARS-CoV-2 virus

22 June 2021

Vaccinating the World: Op-Ed by Pascal Soriot, Project Syndicate

9 June 2021

Infants Need Protection Against RSV: Charting a Path Beyond COVID

13 May 2021

Statement on AstraZeneca’s continued support for the people of India

11 May 2021

Unity is delivering for the world

21 April 2021

Producing a vaccine that is effective in the ‘real-world’

21 March 2021

Achieving diversity in vaccine clinical trials

5 March 2021

A global approach to overcoming the COVID-19 pandemic

2 March 2021

The natural evolution of SARS-CoV-2: How science responds to these challenges

3 February 2021

Pushing boundaries to deliver COVID-19 vaccine across the Globe pt.2

27 January 2021

Innovating Production and Manufacture to meet the Challenge of COVID-19 pt.1

27 January 2021

What does immunogenicity mean in the context of COVID-19 vaccines?

19 November 2020

COVID-19 vaccine AZD1222 is better tolerated in older adults than younger adults with similar immune responses across all age groups

19 November 2020

How will COVID impact youth around the world long-term?

16 October 2020

New normal same cancer

7 October 2020

How the COVID-19 pandemic is changing the shape of cancer clinical trials

4 August 2020

Advancing our discovery of novel coronavirus-neutralising antibodies against COVID-19

9 June 2020

Planning for a sustainable future post-COVID-19

5 June 2020

Researching antibodies to target COVID-19

8 April 2020

Our priorities in responding to the COVID-19 outbreak

AstraZeneca is responding to the COVID-19 (novel coronavirus) outbreak, consistent with our values to follow the science, put patients first and do the right thing. Our priorities are to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities.

13 March 2020

COVID-19 Frequently Asked Questions

For more information regarding AstraZeneca’s response to the COVID-19 pandemic, please visit our FAQ page.

View FAQs

What science can do

These articles aim to simplify and contextualise the science related to COVID-19 and vaccination. A broad spectrum of topics are covered.

View articles

Information for healthcare professionals

Healthcare providers

If you are a registered healthcare provider with questions about COVID-19 and AstraZeneca medications, please visit Astrazeneca's medical information websites at https://medicalinformation.astrazeneca.com/

https://medicalinformation.astrazeneca.com

COVID-19 clinical MDT experience sharing webcast

Leading experts share and discuss the latest scientific insights regarding COVID-19 disease development, as well as clinical experience in treating COVID-19 patients. This content is intended for HealthCare Professionals for medical educational purposes only.

https://covid19webcast.astrazeneca.com

COVID-19 Employee & Leader Toolkits

COVID-19 Employee Toolkit

Created by subject matter experts from across AstraZeneca, this toolkit provides employees with advice and top tips on how to effectively navigate through COVID-19. The resource is available to everyone for external download.

PDF 7,293KB

COVID-19 Leader Toolkit

Created by subject matter experts from across AstraZeneca, this toolkit provides leaders with advice and top tips on how to effectively lead through COVID-19. The resource is available to everyone for external download.

PDF 6,836KB